October 05, 2018
Illumina Inc. overestimated its profit projections by at least $18 million in 2016 even as its product sales were declining, according to a securities class action filed in California federal court Friday accusing the genetic analysis company of costing investors $6.6 billion overnight once its lackluster sales were revealed.